Published in PLoS Genet on February 02, 2012
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol (2013) 1.20
Structural asymmetry in the closed state of mitochondrial Hsp90 (TRAP1) supports a two-step ATP hydrolysis mechanism. Mol Cell (2014) 1.17
Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). Chem Rev (2014) 1.10
Drosophila Trap1 protects against mitochondrial dysfunction in a PINK1/parkin model of Parkinson's disease. Cell Death Dis (2013) 1.06
A mitocentric view of Parkinson's disease. Annu Rev Neurosci (2014) 0.99
α-Synuclein and mitochondria: partners in crime? Neurotherapeutics (2013) 0.95
Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal (2013) 0.94
Heat shock proteins in neurodegenerative disorders and aging. J Cell Commun Signal (2014) 0.93
TRAP1 rescues PINK1 loss-of-function phenotypes. Hum Mol Genet (2013) 0.93
Deletion of the mitochondrial chaperone TRAP-1 uncovers global reprogramming of metabolic networks. Cell Rep (2014) 0.87
Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity. Dis Model Mech (2014) 0.86
Large-scale screen for modifiers of ataxin-3-derived polyglutamine-induced toxicity in Drosophila. PLoS One (2012) 0.85
NADH fluorescence lifetime is an endogenous reporter of α-synuclein aggregation in live cells. FASEB J (2015) 0.84
TRAP1 controls mitochondrial fusion/fission balance through Drp1 and Mff expression. PLoS One (2012) 0.84
Control of cell differentiation by mitochondria, typically evidenced in dictyostelium development. Biomolecules (2013) 0.83
Evaluation of traditional medicines for neurodegenerative diseases using Drosophila models. Evid Based Complement Alternat Med (2014) 0.81
Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochim Biophys Acta (2014) 0.81
Hsp90 regulation of mitochondrial protein folding: from organelle integrity to cellular homeostasis. Cell Mol Life Sci (2012) 0.80
Aberrantly upregulated TRAP1 is required for tumorigenesis of breast cancer. Oncotarget (2015) 0.80
Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons. PLoS One (2013) 0.79
Insights into mitochondrial quality control pathways and Parkinson's disease. J Mol Med (Berl) (2013) 0.79
Mitochondrial control of cell bioenergetics in Parkinson's disease. Free Radic Biol Med (2016) 0.78
Differential submitochondrial localization of PINK1 as a molecular switch for mediating distinct mitochondrial signaling pathways. Cell Signal (2015) 0.77
Model systems of protein-misfolding diseases reveal chaperone modifiers of proteotoxicity. Dis Model Mech (2016) 0.76
αSynuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson's disease. Sci Rep (2017) 0.75
Mitochondrial chaperone TRAP1 activates the mitochondrial UPR and extends healthspan in Drosophila. Mech Ageing Dev (2014) 0.75
Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons. eNeuro (2017) 0.75
Drosophila Clock Is Required in Brain Pacemaker Neurons to Prevent Premature Locomotor Aging Independently of Its Circadian Function. PLoS Genet (2017) 0.75
The Chaperone TRAP1 As a Modulator of the Mitochondrial Adaptations in Cancer Cells. Front Oncol (2017) 0.75
The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology. Front Mol Neurosci (2017) 0.75
Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein? Dis Model Mech (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science (2004) 8.71
A Drosophila model of Parkinson's disease. Nature (2000) 7.82
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A (2000) 5.83
Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci (2007) 5.68
Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci (2006) 4.87
Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol (2008) 4.58
ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J (1998) 4.46
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol (2007) 3.86
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest (2008) 3.23
Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci (2006) 3.20
Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol (1989) 3.11
Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci (2001) 3.10
Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol (2009) 3.02
Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci (2006) 2.85
alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A (2002) 2.81
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology (2007) 2.72
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron (2002) 2.65
Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J Biol Chem (2009) 2.64
Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology (1997) 2.61
Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem (2008) 2.53
Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol (2004) 2.37
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol (2004) 2.30
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
Epidemiology of neurodegeneration. Annu Rev Neurosci (2003) 2.25
Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS One (2009) 2.23
Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J (2010) 2.12
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J (2009) 2.09
C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet (2008) 2.03
Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet (2005) 1.92
Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J Biol Chem (2003) 1.91
Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol Med (2009) 1.89
Mitochondrial dysfunction in Parkinson's disease. Biochim Biophys Acta (2009) 1.77
Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet (2001) 1.74
Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology (1992) 1.71
Genetic modifiers of tauopathy in Drosophila. Genetics (2003) 1.70
Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem (2003) 1.70
Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol (2009) 1.68
Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. PLoS Genet (2007) 1.66
Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J Biol Chem (2007) 1.64
Understanding the molecular causes of Parkinson's disease. Trends Mol Med (2006) 1.62
Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One (2009) 1.59
TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS One (2010) 1.58
Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol (2007) 1.52
Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol (2006) 1.47
Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress (2007) 1.46
Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci (2008) 1.45
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain (2007) 1.45
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Lett (2009) 1.38
Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons. J Biol Chem (2004) 1.31
Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport (2007) 1.30
Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol (2009) 1.26
Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat Rev Neurosci (2002) 1.23
Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem Cell Biol (2009) 1.15
Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J Biol Chem (2004) 1.14
Mitochondrial alterations in Parkinson's disease: new clues. J Neurochem (2008) 1.13
Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci Lett (2008) 1.12
Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis. J Bioenerg Biomembr (2009) 1.11
Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation. Mol Biol Cell (2010) 1.10
Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci Lett (2003) 1.08
Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim Biophys Acta (1995) 1.07
alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci Lett (2009) 1.07
Identification of novel modulators of mitochondrial function by a genome-wide RNAi screen in Drosophila melanogaster. Genome Res (2007) 1.07
The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem (2010) 1.05
Iron chelation study in a normal human hepatocyte cell line suggests that tumor necrosis factor receptor-associated protein 1 (TRAP1) regulates production of reactive oxygen species. J Cell Biochem (2007) 1.02
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Neuroscience (2006) 1.00
Superoxide dismutase overexpression protects dopaminergic neurons in a Drosophila model of Parkinson's disease. Neurobiol Dis (2008) 1.00
Fas/CD95 regulatory protein Faim2 is neuroprotective after transient brain ischemia. J Neurosci (2011) 0.99
Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies. PLoS One (2010) 0.93
Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson's disease. Neurobiol Dis (2010) 0.93
Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson's disease. Front Aging Neurosci (2009) 0.87
Neuromelanin and Parkinson's disease. J Neural Transm Suppl (1983) 0.86
Parkin suppresses c-Jun N-terminal kinase-induced cell death via transcriptional regulation in Drosophila. Mol Cells (2010) 0.81
Genetic factors involved in the pathogenesis of Parkinson's disease. Brain Res Rev (2008) 0.80
Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling. FEBS J (2009) 0.80
Involvement of the mitochondrial apoptotic pathway and nitric oxide synthase in dopaminergic neuronal death induced by 6-hydroxydopamine and lipopolysaccharide. Redox Rep (2010) 0.79
Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci (2007) 5.68
PML in a patient treated with fumaric acid. N Engl J Med (2013) 3.87
Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet (2004) 2.75
Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J Biol Chem (2009) 2.64
Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature. Stroke (2003) 2.63
Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J (2009) 2.37
Repetitive bilateral arm training and motor cortex activation in chronic stroke: a randomized controlled trial. JAMA (2004) 2.36
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol (2013) 2.24
Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol (2004) 2.15
The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO. Mol Cell (2013) 2.12
Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J (2010) 2.12
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J (2009) 2.09
Systematic review of early recurrent stenosis after carotid angioplasty and stenting. Stroke (2004) 2.04
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J (2011) 1.80
Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol (2002) 1.79
Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res (2004) 1.76
Short and long-term motor skill learning in an accelerated rotarod training paradigm. Neurobiol Learn Mem (2004) 1.72
Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci (2002) 1.72
Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science (2008) 1.67
Transgenic rat model of Huntington's disease. Hum Mol Genet (2003) 1.66
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem (2004) 1.61
TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS One (2010) 1.58
Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J Neurosci (2007) 1.54
Clinical predictors of transient ischemic attack, stroke, or death within 30 days of carotid angioplasty and stenting. Stroke (2005) 1.53
Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain (2010) 1.52
The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation (2012) 1.50
Deep brain stimulation. Cell Tissue Res (2004) 1.42
Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.41
Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology (2006) 1.40
Pathogenic mutations inactivate parkin by distinct mechanisms. J Neurochem (2005) 1.38
Motor skill learning depends on protein synthesis in motor cortex after training. J Neurosci (2004) 1.37
Neuroligin-4 is localized to glycinergic postsynapses and regulates inhibition in the retina. Proc Natl Acad Sci U S A (2011) 1.37
Mitochondrial protein quality control by the proteasome involves ubiquitination and the protease Omi. J Biol Chem (2008) 1.30
The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. J Neurochem (2006) 1.28
Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci (2008) 1.28
Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP. Mol Biol Cell (2006) 1.25
Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system. EMBO J (2003) 1.25
Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res (2002) 1.23
Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat (2004) 1.22
Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet (2003) 1.22
Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci (2007) 1.20
Stress-protective signalling of prion protein is corrupted by scrapie prions. EMBO J (2008) 1.18
Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J Neurochem (2006) 1.16
Depression comorbidity in spinocerebellar ataxia. Mov Disord (2011) 1.15
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res (2002) 1.15
Lesion location alters brain activation in chronically impaired stroke survivors. Neuroimage (2004) 1.14
Relation between regional functional MRI activation and vascular reactivity to carbon dioxide during normal aging. J Cereb Blood Flow Metab (2003) 1.14
Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol (2013) 1.14
Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol (2011) 1.13
Feasibility of prehospital teleconsultation in acute stroke--a pilot study in clinical routine. PLoS One (2012) 1.12
RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. Proc Natl Acad Sci U S A (2007) 1.11
Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage (2004) 1.10
Drosophila tao controls mushroom body development and ethanol-stimulated behavior through par-1. J Neurosci (2011) 1.08
Aberrant folding of pathogenic Parkin mutants: aggregation versus degradation. J Biol Chem (2008) 1.07
Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery. Mol Ther (2011) 1.06
Pathogenic mutations located in the hydrophobic core of the prion protein interfere with folding and attachment of the glycosylphosphatidylinositol anchor. J Biol Chem (2004) 1.05
Characterization of motor skill and instrumental learning time scales in a skilled reaching task in rat. Behav Brain Res (2004) 1.05
Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. J Neurosci Res (2002) 1.05
Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. J Neurochem (2008) 1.05
Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP. J Neurochem (2008) 1.04
Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord (2009) 1.04
Affinity for phosphatidylinositol 4,5-bisphosphate determines muscarinic agonist sensitivity of Kv7 K+ channels. J Gen Physiol (2009) 1.04
Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci Lett (2008) 1.04
Investigating function and connectivity of morphometric findings--exemplified on cerebellar atrophy in spinocerebellar ataxia 17 (SCA17). Neuroimage (2012) 1.01
Diagnostic challenge and therapeutic dilemma in necrotizing myopathy. Neurology (2013) 1.01
Co-enzyme Q10 and idebenone use in Friedreich's ataxia. J Neurochem (2013) 1.01
Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain (2013) 1.00
Fas/CD95 regulatory protein Faim2 is neuroprotective after transient brain ischemia. J Neurosci (2011) 0.99
Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol (2005) 0.97
Inflammation-induced alteration of astrocyte mitochondrial dynamics requires autophagy for mitochondrial network maintenance. Cell Metab (2013) 0.97
The C-terminal globular domain of the prion protein is necessary and sufficient for import into the endoplasmic reticulum. J Biol Chem (2003) 0.97
Impaired complex IV activity in response to loss of LRPPRC function can be compensated by mitochondrial hyperfusion. Proc Natl Acad Sci U S A (2013) 0.96
Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem (2007) 0.96
Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol Med (2002) 0.96
The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease. FASEB J (2007) 0.96
The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Dev (2012) 0.95
Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration. J Clin Invest (2015) 0.95
Transient expression of Nxf, a bHLH-PAS transactivator induced by neuronal preconditioning, confers neuroprotection in cultured cells. Brain Res (2007) 0.95
Drosophila melanogaster as a model organism for Alzheimer's disease. Mol Neurodegener (2013) 0.95
Alternate-form reliability of the Montreal cognitive assessment screening test in a clinical setting. Dement Geriatr Cogn Disord (2012) 0.94
Palmitoylation is a sorting determinant for transport to the myelin membrane. J Cell Sci (2005) 0.94
TRAP1 rescues PINK1 loss-of-function phenotypes. Hum Mol Genet (2013) 0.93
Spinocerebellar ataxia types 1, 2, 3 and 6: the clinical spectrum of ataxia and morphometric brainstem and cerebellar findings. Cerebellum (2012) 0.93
Emergence of brain-derived neurotrophic factor-induced postsynaptic potentiation of NMDA currents during the postnatal maturation of the Kolliker-Fuse nucleus of rat. J Physiol (2008) 0.93
Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson's disease. Neurobiol Dis (2010) 0.93
Targeted ablation of oligodendrocytes triggers axonal damage. PLoS One (2011) 0.93